JP6670860B2 - 導電性高分子を利用したセルフリーdna検出用構造体およびその用途 - Google Patents
導電性高分子を利用したセルフリーdna検出用構造体およびその用途 Download PDFInfo
- Publication number
- JP6670860B2 JP6670860B2 JP2017566695A JP2017566695A JP6670860B2 JP 6670860 B2 JP6670860 B2 JP 6670860B2 JP 2017566695 A JP2017566695 A JP 2017566695A JP 2017566695 A JP2017566695 A JP 2017566695A JP 6670860 B2 JP6670860 B2 JP 6670860B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cell
- dna
- carcinoma
- free dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920001940 conductive polymer Polymers 0.000 title claims description 55
- 238000001514 detection method Methods 0.000 title claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 120
- 201000011510 cancer Diseases 0.000 claims description 82
- 238000000034 method Methods 0.000 claims description 71
- 210000004369 blood Anatomy 0.000 claims description 52
- 239000008280 blood Substances 0.000 claims description 52
- 239000002070 nanowire Substances 0.000 claims description 42
- 239000000523 sample Substances 0.000 claims description 32
- 229920000128 polypyrrole Polymers 0.000 claims description 29
- 238000000926 separation method Methods 0.000 claims description 28
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 23
- 201000005202 lung cancer Diseases 0.000 claims description 21
- 208000020816 lung neoplasm Diseases 0.000 claims description 21
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 19
- 206010006187 Breast cancer Diseases 0.000 claims description 17
- 208000026310 Breast neoplasm Diseases 0.000 claims description 17
- 201000009030 Carcinoma Diseases 0.000 claims description 15
- 238000004458 analytical method Methods 0.000 claims description 15
- 238000004393 prognosis Methods 0.000 claims description 13
- 206010009944 Colon cancer Diseases 0.000 claims description 11
- 239000012472 biological sample Substances 0.000 claims description 10
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 9
- 208000014018 liver neoplasm Diseases 0.000 claims description 9
- 210000004072 lung Anatomy 0.000 claims description 9
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 8
- 206010038389 Renal cancer Diseases 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 8
- 201000010982 kidney cancer Diseases 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 206010027406 Mesothelioma Diseases 0.000 claims description 7
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 7
- 206010039491 Sarcoma Diseases 0.000 claims description 7
- 206010038038 rectal cancer Diseases 0.000 claims description 7
- 201000001275 rectum cancer Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 201000004101 esophageal cancer Diseases 0.000 claims description 5
- 201000010536 head and neck cancer Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 210000003296 saliva Anatomy 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- 206010061424 Anal cancer Diseases 0.000 claims description 4
- 208000002151 Pleural effusion Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 4
- 201000007538 anal carcinoma Diseases 0.000 claims description 4
- 210000003567 ascitic fluid Anatomy 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 206010024627 liposarcoma Diseases 0.000 claims description 4
- 206010027191 meningioma Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 3
- 201000009036 biliary tract cancer Diseases 0.000 claims description 3
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 3
- 201000000053 blastoma Diseases 0.000 claims description 3
- 230000005611 electricity Effects 0.000 claims description 3
- 201000008184 embryoma Diseases 0.000 claims description 3
- 230000002357 endometrial effect Effects 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims description 3
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 3
- 208000030940 penile carcinoma Diseases 0.000 claims description 3
- 201000008174 penis carcinoma Diseases 0.000 claims description 3
- 201000003804 salivary gland carcinoma Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 210000003445 biliary tract Anatomy 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 230000002250 progressing effect Effects 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 116
- 239000002086 nanomaterial Substances 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 22
- 239000010931 gold Substances 0.000 description 22
- 238000011282 treatment Methods 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 13
- 210000002381 plasma Anatomy 0.000 description 13
- 108091092240 circulating cell-free DNA Proteins 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 239000010408 film Substances 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 238000003745 diagnosis Methods 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 239000013615 primer Substances 0.000 description 7
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 208000019065 cervical carcinoma Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- -1 phosphotriesters Chemical class 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 229910021607 Silver chloride Inorganic materials 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 5
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000007847 digital PCR Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012421 spiking Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 101150039808 Egfr gene Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 description 3
- 206010057644 Testis cancer Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000000970 chrono-amperometry Methods 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical group P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 108700021358 erbB-1 Genes Proteins 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 208000007538 neurilemmoma Diseases 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 238000005502 peroxidation Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000003746 surface roughness Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 201000003120 testicular cancer Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
- 206010069755 K-ras gene mutation Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 238000011394 anticancer treatment Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010291 electrical method Methods 0.000 description 2
- 238000002848 electrochemical method Methods 0.000 description 2
- 201000003914 endometrial carcinoma Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 239000000138 intercalating agent Substances 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002073 nanorod Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 150000004767 nitrides Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 229920001197 polyacetylene Polymers 0.000 description 2
- 229920000767 polyaniline Polymers 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 229920000123 polythiophene Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 235000019592 roughness Nutrition 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical class [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 208000012991 uterine carcinoma Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 241000593245 Bionia Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000004139 Choroid Plexus Neoplasms Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 description 1
- 239000012625 DNA intercalator Substances 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100027100 Echinoderm microtubule-associated protein-like 4 Human genes 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 description 1
- 101001057929 Homo sapiens Echinoderm microtubule-associated protein-like 4 Proteins 0.000 description 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101001074727 Homo sapiens Ribonucleoside-diphosphate reductase large subunit Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 102000007298 Mucin-1 Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108090000119 Nucleotidyltransferases Proteins 0.000 description 1
- 102000003832 Nucleotidyltransferases Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100036320 Ribonucleoside-diphosphate reductase large subunit Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 239000000980 acid dye Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000231 atomic layer deposition Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000002801 charged material Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000002322 conducting polymer Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 238000000349 field-emission scanning electron micrograph Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000005558 fluorometry Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- AMGQUBHHOARCQH-UHFFFAOYSA-N indium;oxotin Chemical compound [In].[Sn]=O AMGQUBHHOARCQH-UHFFFAOYSA-N 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 238000001725 laser pyrolysis Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000002082 metal nanoparticle Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000002090 nanochannel Substances 0.000 description 1
- 239000002071 nanotube Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004649 neutrophil actin dysfunction Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920001464 poly(sodium 4-styrenesulfonate) Polymers 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229960000286 proflavine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 102200048928 rs121434568 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002207 thermal evaporation Methods 0.000 description 1
- 238000000427 thin-film deposition Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 208000010579 uterine corpus leiomyoma Diseases 0.000 description 1
- 201000007954 uterine fibroid Diseases 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002569 water oil cream Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L101/00—Compositions of unspecified macromolecular compounds
- C08L101/12—Compositions of unspecified macromolecular compounds characterised by physical features, e.g. anisotropy, viscosity or electrical conductivity
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/026—Wholly aromatic polyamines
- C08G73/0266—Polyanilines or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
- C08G73/0605—Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms
- C08G73/0611—Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms with only one nitrogen atom in the ring, e.g. polypyrroles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Description
(i)平面構造体またはナノ構造体を形成する導電性高分子の表面を正電荷に改質する段階;
(ii)生物学的試料を処理して前記導電性高分子にcfDNAを付着させる段階;および
(iii)電気的信号を加えて前記導電性高分子からcfDNAを検出および分離させる段階。
「対象」または「患者」は、ヒト、ウシ、イヌ、モルモット、ウサギ、トリ、昆虫などを含んで治療が要求される任意の単一個体を意味する。また、任意の疾病臨床所見を示さない臨床研究試験に参加した任意の対象または力学研究に参加した対象または対照群として使用された対象が対象に含まれる。本発明の一実施例では、ヒトを対象とした。
本発明のセルフリーDNA検出用構造体は、導電性高分子で構成されることを特徴とする。
本発明は、一態様において、前記導電性高分子としてcfDNAの検出および分離、好ましくは、ctDNAの検出および分離用構造体およびその用途に関する。
分析物質を認識するために生体物質を電気的に蒸着された(electro−deposition)導電性高分子に固定化する技術が必要である。
本発明の導電性高分子よりなる構造体は、循環セルフリーDNA(cfDNA)、特に循環腫瘍DNA(ctDNA)を検出および分離するのに有用である。
したがって、さらに他の観点において、本発明は、前記ナノ構造体を利用する循環セルフリーDNA(cfDNA)を検出または分離する方法に関する。このような方法に関する概念的な模式図を図1に示した。
(i)平面構造体またはナノ構造体を形成する導電性高分子の表面を正電荷に改質する段階;
(ii)生物学的試料を処理して前記導電性高分子にcfDNAを付着させる段階;および
(iii)電気的信号を加えて前記導電性高分子からcfDNAを検出または分離させる段階。
さらに他の観点において、本発明は、前記構造体を含む循環セルフリーDNA(cfDNA)を検出または分離用装置、例えばキットに関する。
さらに他の観点において、本発明は、循環腫瘍DNA(ctDNA)を検出および分離して分析することを含む、対象者で癌の発病および予後を診断するために情報を提供する方法に関する。
1.Ppy−コーティングされたAu NWs(Ppy/Au NWs)の製作
従来、熱蒸着(thermal evaporation)技術を利用して、略150nm厚さのAuレイヤーをAAO鋳型(Whatman;ポア直径、100nm)の一面にコーティングした。金−プレーティング溶液(Orotemps 24 RTU Rack)を利用してAuナノワイヤーを電気化学的にAu−backed AAOメンブレンのポア内に成長させ、循環電圧電流法(cyclic voltammetry)を適用して100mV/s速度で1.1〜0Vの電位範囲を使用してPpyをAuナノワイヤーの表面に蒸着するようにして、Ppy−コーティングされたAu NWsを製作した。
NCC臨床試験審査委員会により承認を受けた手続を利用して抗凝固剤EDTAを含有する真空採血器チューブに全血を収集した。冷蔵遠心分離機(3000xg、10min)を利用して血漿を分離した。Ppy/Au NWsプラットホームの捕獲および放出効率を評価するために、健康な供与者から200μlの血漿内にDNAラダー(ladder)のex vivoスパイキング(spiking)により製作された人工血液サンプルを利用してこれらをテストした。臨床適用のために、3名の健康なボランティアおよび乳癌と肺癌患者17名から血液サンプルを収集した。
DNA捕獲効率を評価する前に、個別的なナノワイヤーとDNAの相互作用を促進するために、過酸化したPpy/Au NWsを血液サンプルに30分間常温で沈漬した:前記サンプルは、(i)ヒト血漿にスパイクしたDNA分子(250ng/mL)を含有する人工サンプル、または(ii)3名の健康な供与者および17名の癌患者から収得した未処理の血漿サンプル(200μL〜1mL)である。
すべてのプライマーを合成して使用した(マクロジェン、韓国)
QIAamp循環核酸キットを利用して1mLの血漿からcfDNAを抽出した。簡略に述べると、血漿サンプルをプロテイナーゼKおよび溶解バッファーを利用して溶解し、循環する核酸を真空圧力を利用してシリカに結合させた。DNAフラグメントを数回の洗浄段階後に、メンブレンから回収した。
cfDNAでEGFR突然変異を、PrimePCR ddPCR突然変異分析法を利用してQX200 ddPCR system(BioRad,CA,USA)上でEGFR L858Rおよびエクソン19欠失(p.E746−A750del)に対して検出した。水−油エマルジョンドロップレットを8μLのcfDNA、10μLのddPCRスーパーミックス、および2μLのターゲットプライマーおよびプローブを含有するPCR混合物から生成した。前記ドロップレットを生成した後、PCRをサーマルサイクラーで行った。増幅されたDNAの少なくとも一つのコピーを含有する陽性(positive)ドロップレットを蛍光分析法に対するドロップレットリーダーにより検出することができた。
一次腫瘍組織でEGFR遺伝子位置をPCR−directシーケンシング方法を利用して検出した。ゲノムDNAを抽出し、EGFR遺伝子のエクソン19および21に対する特異的プライマーを利用して増幅した。PCR産物をBigDyeターミネーターサイクルシーケンシングキットを利用してシーケンシングし、ABI PRISM 3100 DNA分析装置(Applied Biosystems,CA,USA)を利用して分析した。
電気刺激を用いた効果的なポリピロールの表面改質性質を利用してDNAラダーを血漿にスパイクして、cfDNAの濃縮および分離を試みた。また、扁平な表面よりナノワイヤー構造体に顕著に多くのcfDNAが付着/分離し得ることを確認した。
乳癌患者の血液を利用して導電性ナノ構造体の表面に付着したcfDNAを蛍光染料であるSYBR Green/PICO Greenを用いて共焦点顕微鏡で観察した。
ポリピロールナノワイヤー構造体だけでなく、本発明者らは、追加に、ポリピロール平面構造体の表面においても血液内の循環cfDNAの分離が可能であることを確認した。
Claims (14)
- 正電荷を帯びるように表面改質した導電性高分子を含む、セルフリー(cell−free)DNAの検出および分離用構造体であって、前記導電性高分子はポリピロールであり、前記構造体はナノワイヤーである、セルフリーDNAの検出および分離用構造体。
- 前記セルフリーDNAは、循環腫瘍DNA(circulating tumor DNA,ctDNA)であることを特徴とする、請求項1に記載のセルフリーDNAの検出および分離用構造体。
- 請求項1又は2に記載のセルフリーDNAの検出および分離用構造体を含む、セルフリーDNA検出および分離用キット。
- (i)ナノワイヤーを形成するポリピロールの表面を正電荷に改質する段階と;
(ii)生物学的試料を処理して前記ポリピロールにcfDNA(cell free DNA)を付着させる段階と;
(iii)電気的信号を加えて前記ポリピロールからcfDNAを検出または分離させる段階と;
を含むセルフリーDNAを検出または分離する方法。 - 前記生物学的試料は、血液、骨髄、胸水、腹膜液、脊髄液、尿、および唾液よりなる群から選択されることを特徴とする、請求項4に記載のセルフリーDNAを検出または分離する方法。
- 前記生物学的試料は、血液であることを特徴とする、請求項5に記載のセルフリーDNAを検出または分離する方法。
- (ii)段階で、前記cfDNAを付着させる段階は、0.8〜1.2Vで20〜40秒間電気を加えて行われることを特徴とする、請求項4に記載のセルフリーDNAを検出または分離する方法。
- (iii)段階で、前記cfDNAを検出または分離させる段階は、−1.3〜−1.0Vで4〜6分間電気的信号を加えて行われることを特徴とする、請求項4に記載のセルフリーDNAを検出または分離する方法。
- 前記セルフリーDNAは、循環腫瘍DNAであることを特徴とする、請求項4に記載のセルフリーDNAを検出または分離する方法。
- 請求項1又は2に記載のセルフリーDNAの検出および分離用構造体を利用してサンプルから循環腫瘍DNA(ctDNA)を検出または分離して分析することを含む、対象者の癌の発病および予後を診断するための情報を提供する方法。
- 前記癌は、癌腫(carcinoma)、リンパ腫(lymphoma)、芽細胞腫(blastoma)、肉腫(sarcoma)、脂肪肉腫(liposarcoma)、神経内分泌腫瘍(neuroendocrine tumor)、中皮腫(mesothelioma)、神経鞘腫(schwanoma)、髄膜腫(meningioma)、腺癌(adenocarcinoma)、黒色腫(melanoma)、白血病(leukemia)、悪性リンパ腫(lymphoidmalignancy)、扁平細胞癌腫(squamous cell cancer)、扁平上皮細胞癌(epithelial squamous cell cancer)、肺癌(lung cancer)、小細胞肺癌(small−cell lung cancer)、非小細胞肺癌(non−small cell lung cancer)、肺腺癌(adenocarcinoma of the lung)、肺扁平上皮癌(squamous carcinoma of the lung)、腹膜癌(cancer of the peritoneum)、肝細胞癌(hepatocellular cancer)、胃癌種(gastric or stomach cancer)、胃腸管癌(gastrointestinal cancer)、膵臓癌(pancreatic cancer)、脳腫瘍、膠芽腫(glioblastoma)、子宮頸癌(cervical cancer)、卵巣癌(ovarian cancer)、肝癌(liver cancer)、膀胱癌(bladder cancer)、肝細胞癌(hepatoma)、乳癌(breast cancer)、結腸癌(colon cancer)、直腸癌(rectal cancer)、結腸直腸癌(colorectal cancer)、子宮内膜または子宮癌(endometrial or uterine carcinoma)、唾液腺癌(salivary gland carcinoma)、腎臓癌(kidney and renal cancer)、前立腺癌(prostate cancer)、外陰癌(vulval cancer)、甲状腺癌(thyroid cancer)、肝癌腫(hepatic carcinoma)、肛門癌腫(anal carcinoma)、陰茎癌(penile carcinoma)、睾丸癌(testicular cancer)、食道癌(esophageal cancer)、胆道癌(biliary tract)および頭頸部癌(head and neck cancer)よりなる群から選択されることを特徴とする、請求項10に記載の方法。
- 前記癌は、乳癌、肺癌、胃癌、肝癌または膵臓癌であることを特徴とする、請求項11に記載の方法。
- 前記分析は、サンプルからctDNAの量(濃度)、コピー数または塩基配列を分析することを特徴とする、請求項10に記載の方法。
- ctDNAの量(濃度)またはコピー数が増加する場合、癌が発生または進行するという情報を提供することを特徴とする、請求項13に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150089267A KR101701618B1 (ko) | 2015-06-23 | 2015-06-23 | 전도성 고분자를 이용한 세포 유리 dna 검출용 구조체 및 이의 용도 |
KR10-2015-0089267 | 2015-06-23 | ||
PCT/KR2016/006728 WO2016209011A1 (ko) | 2015-06-23 | 2016-06-23 | 전도성 고분자를 이용한 세포 유리 dna 검출용 구조체 및 이의 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018522550A JP2018522550A (ja) | 2018-08-16 |
JP6670860B2 true JP6670860B2 (ja) | 2020-04-01 |
Family
ID=57585770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017566695A Active JP6670860B2 (ja) | 2015-06-23 | 2016-06-23 | 導電性高分子を利用したセルフリーdna検出用構造体およびその用途 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20170051275A1 (ja) |
EP (1) | EP3315607B1 (ja) |
JP (1) | JP6670860B2 (ja) |
KR (1) | KR101701618B1 (ja) |
CN (1) | CN107980061A (ja) |
HK (1) | HK1254619A1 (ja) |
WO (1) | WO2016209011A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108330171A (zh) * | 2017-09-27 | 2018-07-27 | 天津诺禾医学检验所有限公司 | 检测egfr基因第19号外显子缺失突变的试剂盒、方法及其应用 |
KR102249506B1 (ko) | 2017-10-30 | 2021-05-11 | 주식회사 인퓨전텍 | 동형2기능성 이미도에스터를 이용한 액체생검 유래 생체물질의 추출 방법 |
JP7239973B2 (ja) * | 2017-12-19 | 2023-03-15 | 国立大学法人山口大学 | 前癌病変又は癌の有無の予測を補助する方法 |
US20210010064A1 (en) * | 2018-03-14 | 2021-01-14 | The Trustees Of The University Of Pennsylvania | Enrichment of nucleic acids |
US20210215681A1 (en) * | 2018-06-01 | 2021-07-15 | Genopsy Co., Ltd. | Method for detection of unstable cell-free dna and device using same |
KR20200117917A (ko) * | 2019-04-05 | 2020-10-14 | 주식회사 제놉시 | Cfdna를 이용한 암 진단방법 |
WO2021231862A1 (en) * | 2020-05-14 | 2021-11-18 | Georgia Tech Research Corporation | Methods of detecting the efficacy of anticancer agents |
KR102552632B1 (ko) * | 2020-11-06 | 2023-07-06 | 사회복지법인 삼성생명공익재단 | 중추신경계 림프종을 진단하기 위한 마커, 이를 포함하는 중추신경계 림프종 진단 키트 및 중추신경계 림프종을 진단하는 방법 |
EP4281556A1 (en) * | 2021-01-25 | 2023-11-29 | The Broad Institute Inc. | Methods and compositions for increasing the concentration of cell free dna |
CN115253682B (zh) * | 2022-07-29 | 2024-02-02 | 烟台至公生物医药科技有限公司 | 一种膀胱癌细胞捕获装置及捕获方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776672A (en) * | 1990-09-28 | 1998-07-07 | Kabushiki Kaisha Toshiba | Gene detection method |
US5440025A (en) * | 1992-03-12 | 1995-08-08 | University Of Massachusetts At Lowell | Process for separating nucleic acid polymers |
KR100399475B1 (ko) | 1998-02-12 | 2003-09-29 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 순환 중인 암세포의 신속하고 효과적인 분리 방법 및 이를위한 제제 |
US6855426B2 (en) | 2001-08-08 | 2005-02-15 | Nanoproducts Corporation | Methods for producing composite nanoparticles |
JP4593557B2 (ja) | 2003-02-27 | 2010-12-08 | ベリデックス・リミテッド・ライアビリティ・カンパニー | 循環腫瘍細胞(ctc):転移癌患者における増悪までの時間、生存および療法に対する応答の早期評価 |
DE10311315A1 (de) * | 2003-03-14 | 2004-09-30 | Apibio Sas | Verfahren und Vorrichtung zur Detektion von Biomolekülen |
US7910064B2 (en) | 2003-06-03 | 2011-03-22 | Nanosys, Inc. | Nanowire-based sensor configurations |
US20090294303A1 (en) | 2004-10-12 | 2009-12-03 | The Regents Of The University Of California | method for identifying compounds that affect a transport of a protein through menbrane trafficking pathway |
US8034222B2 (en) * | 2004-10-26 | 2011-10-11 | The Regents Of The University Of California | Conducting polymer nanowire sensors |
CN101243316A (zh) * | 2005-06-30 | 2008-08-13 | 阿普尔拉股份有限公司 | 含有导电聚合物的多孔复合电极 |
KR100700090B1 (ko) * | 2005-09-23 | 2007-03-28 | 삼성전자주식회사 | 이온투과성 폴리머로 코팅된 전극을 이용한 핵산 정제 방법및 그 장치 |
KR100730350B1 (ko) | 2005-10-17 | 2007-06-19 | 삼성전자주식회사 | 표면처리된 나노포어를 이용한 dna 검출방법 및검출장치 |
BRPI0712225A8 (pt) | 2006-06-02 | 2019-01-22 | Pfizer Producs Inc | métodos para prever e monitorar a eficácia da terapia antagonista de igf-1r |
CN101563134A (zh) | 2006-10-18 | 2009-10-21 | 派利尼斯有限公司 | 用于诊断和治疗男性低生育力的方法和药物组合物 |
KR100940598B1 (ko) * | 2007-10-12 | 2010-02-04 | 부산대학교 산학협력단 | Dna검출용 마이크로칩 및 이를 이용한 검출방법 |
US8070928B2 (en) * | 2007-12-31 | 2011-12-06 | Intel Corporation | Nanofabricated structures for electric field-assisted nucleic acid extraction |
US20100041048A1 (en) * | 2008-07-31 | 2010-02-18 | The Johns Hopkins University | Circulating Mutant DNA to Assess Tumor Dynamics |
JP5080434B2 (ja) | 2008-12-05 | 2012-11-21 | ベリデックス・リミテッド・ライアビリティ・カンパニー | 生物学的試料から標的生体部分を単離する方法およびそのためのキット |
WO2010151817A1 (en) * | 2009-06-25 | 2010-12-29 | The Regents Of The University Of California | Probe immobilization and signal amplification for polymer-based biosensor |
JP5704590B2 (ja) | 2010-02-05 | 2015-04-22 | 国立大学法人東京農工大学 | サイズ選択マイクロキャビティアレイを用いた循環腫瘍細胞の検出 |
CN101812176B (zh) * | 2010-04-13 | 2012-01-25 | 无锡中美亿芯生物科技有限公司 | 一种具有生物活性的导电聚苯胺及其制备方法和应用 |
EP2715351B1 (en) * | 2011-05-24 | 2016-10-19 | The Regents of The University of California | Method for exosomal biomarker detection by electric field-induced release and measurement |
JP5854456B2 (ja) | 2011-08-23 | 2016-02-09 | 日立化成株式会社 | 癌細胞濃縮フィルター |
KR101473078B1 (ko) * | 2013-01-02 | 2014-12-17 | 연세대학교 산학협력단 | 암 진단 및 치료용 유-무기 나노복합체 |
US9999856B2 (en) * | 2013-07-26 | 2018-06-19 | General Electric Company | Methods for electroelution of biomolecules |
KR101545160B1 (ko) * | 2013-11-25 | 2015-08-19 | 국립암센터 | 전도성 고분자를 포함하는 세포의 검출 및 회수용 조성물 |
JP2017512483A (ja) * | 2014-04-08 | 2017-05-25 | バイオロジカル ダイナミクス,インク. | 生体物質の単離のための改良された装置 |
-
2015
- 2015-06-23 KR KR1020150089267A patent/KR101701618B1/ko active IP Right Grant
-
2016
- 2016-06-23 JP JP2017566695A patent/JP6670860B2/ja active Active
- 2016-06-23 EP EP16814724.7A patent/EP3315607B1/en active Active
- 2016-06-23 WO PCT/KR2016/006728 patent/WO2016209011A1/ko active Application Filing
- 2016-06-23 CN CN201680047982.7A patent/CN107980061A/zh active Pending
- 2016-08-24 US US15/245,818 patent/US20170051275A1/en not_active Abandoned
-
2018
- 2018-10-23 HK HK18113585.4A patent/HK1254619A1/zh unknown
- 2018-12-21 US US16/229,772 patent/US11352616B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3315607A4 (en) | 2018-12-26 |
HK1254619A1 (zh) | 2019-07-26 |
KR101701618B1 (ko) | 2017-02-13 |
JP2018522550A (ja) | 2018-08-16 |
KR20170000258A (ko) | 2017-01-02 |
CN107980061A (zh) | 2018-05-01 |
US20190376056A1 (en) | 2019-12-12 |
EP3315607A1 (en) | 2018-05-02 |
US11352616B2 (en) | 2022-06-07 |
US20170051275A1 (en) | 2017-02-23 |
WO2016209011A1 (ko) | 2016-12-29 |
EP3315607B1 (en) | 2021-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6670860B2 (ja) | 導電性高分子を利用したセルフリーdna検出用構造体およびその用途 | |
Preethi et al. | Liquid biopsy: Exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer | |
US11845975B2 (en) | Extract from a body fluid comprising a micro RNA | |
Wang et al. | High-efficiency isolation and rapid identification of heterogeneous circulating tumor cells (CTCs) using dual-antibody-modified fluorescent-magnetic nanoparticles | |
US10273527B2 (en) | Nanopore-facilitated single molecule detection of nucleic acids | |
WO2021049671A1 (ja) | マイクロrnaを含む体液抽出物 | |
Jiao et al. | Somatic mutations in the Notch, NF‐KB, PIK3CA, and Hedgehog pathways in human breast cancers | |
Chen et al. | Clinical applications of NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells | |
Li et al. | Efficient capture and high activity release of circulating tumor cells by using TiO2 nanorod arrays coated with soluble MnO2 nanoparticles | |
Xiao et al. | Peptide nucleic acid-functionalized nanochannel biosensor for the highly sensitive detection of tumor exosomal microRNA | |
US20200308657A1 (en) | Novel gene classifiers and uses thereof in skin cancers | |
KR102526916B1 (ko) | Cfdna를 이용한 위암 진단방법 | |
CA2916848C (en) | Detection of brain cancer | |
Jeon et al. | Efficient capture and isolation of tumor-related circulating cell-free DNA from cancer patients using electroactive conducting polymer nanowire platforms | |
Guo et al. | Recent progress of nanostructure-based enrichment of circulating tumor cells and downstream analysis | |
JP2018535651A (ja) | 診断方法および装置 | |
JP2021526029A (ja) | 不安定セルフリーdnaを検出する方法およびそれを使用するデバイス | |
Shen et al. | A novel fluorescence biosensor for the detection and imaging of tumor-related mRNA in living cells based on Au//hGNPs-FA nanocarrier | |
WO2016057474A1 (en) | Systems and methods for localized surface plasmon resonance biosensing | |
JP7241422B2 (ja) | Eml4-alk遺伝子変異分析方法 | |
Park et al. | Ultrasensitive and Rapid Circulating Tumor DNA Liquid Biopsy Using Surface-Confined Gene Amplification on Dispersible Magnetic Nano-Electrodes | |
WO2013150167A2 (es) | Modelo de expresión de microarn como indicador de supervivencia en pacientes de cancer colorrectal metastásico | |
KR20160084174A (ko) | 루테리알의 핵산 서열 변이를 이용한 환자 맞춤형 치료제 스크리닝 방법 | |
WO2014096500A1 (es) | Método de obtención de datos útiles para el diagnóstico diferencial del cáncer de pulmón |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180215 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181219 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190110 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190408 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190605 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190828 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20191218 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20200115 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200212 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200302 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6670860 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |